Edition:
India

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

80.58USD
15 Dec 2017
Change (% chg)

$-3.29 (-3.92%)
Prev Close
$83.87
Open
$82.85
Day's High
$83.27
Day's Low
$77.25
Volume
705,585
Avg. Vol
286,970
52-wk High
$192.94
52-wk Low
$77.25

Chart for

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $6,492.51
Shares Outstanding(Mil.): 54.18
Dividend: --
Yield (%): --

Financials

BRIEF-Tesaro secures $500 million non-dilutive term loan financing

* Tesaro secures $500 million non-dilutive term loan financing

21 Nov 2017

BRIEF-Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

* Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

20 Nov 2017

BRIEF-Tesaro reports Q3 loss per share $0.47

* Q3 revenue $142.8 million versus I/B/E/S view $132.8 million

08 Nov 2017

BRIEF-Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy

* Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy

26 Oct 2017

BRIEF-Evotec, Tesaro enter partnership on novel immuno-oncology agents

* dgap-news: evotec and tesaro enter strategic partnership to discover novel immuno-oncology agents

26 Oct 2017

FDA approves intravenous version of Tesaro drug for chemotherapy nausea

Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

26 Oct 2017

FDA approves intravenous version of Tesaro drug for chemotherapy nausea

Oct 25 Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

26 Oct 2017

Tesaro's ovarian cancer drug gets EU agency backing

A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

15 Sep 2017

Tesaro's ovarian cancer drug gets EU agency backing

Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

15 Sep 2017

BRIEF-Tesaro Inc Q2 loss per share $2.82

* Q2 earnings per share view $-2.49 -- Thomson Reuters I/B/E/S

09 Aug 2017

Earnings vs. Estimates